1.05
+0.005(+0.48%)
Currency In USD
| Previous Close | 1.05 |
| Open | 1.04 |
| Day High | 1.05 |
| Day Low | 1.04 |
| 52-Week High | 1.69 |
| 52-Week Low | 0.7 |
| Volume | 19,140 |
| Average Volume | 334,282 |
| Market Cap | 38.48M |
| PE | -2.92 |
| EPS | -0.36 |
| Moving Average 50 Days | 0.93 |
| Moving Average 200 Days | 1.1 |
| Change | 0.01 |
If you invested $1000 in RenovoRx, Inc. (RNXT) since IPO date, it would be worth $143.94 as of January 14, 2026 at a share price of $1.045. Whereas If you bought $1000 worth of RenovoRx, Inc. (RNXT) shares 3 years ago, it would be worth $264.56 as of January 14, 2026 at a share price of $1.045.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
RenovoRx to Participate in AlphaNorth Capital Event, January 16-18, 2026
GlobeNewswire Inc.
1 hours ago
CEO Shaun Bagai to Discuss RenovoRx’s Commercial and Clinical Program ProgressMOUNTAIN VIEW, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (Nasdaq: RNXT) (“RenovoRx” or “the Company”), a life sciences company developing innovative target
RenovoRx To Announce Promising New Clinical Data Using its TAMP™ Therapy Platform in an Abstract to be Presented at ASCO GI 2026
GlobeNewswire Inc.
Jan 08, 2026 1:30 PM GMT
New Pharmacokinetic (PK) and Pharmacodynamic Data from Sub-Study in Phase III Trial Strengthens Scientific Basis for RenovoRx’s TAMP Therapy Platform as a Targeted Drug-Delivery Approach Data Shows a PK Profile that May Improve Clinical Efficacy and
RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026
GlobeNewswire Inc.
Dec 11, 2025 1:30 PM GMT
The Accepted Abstract Provides Supportive Evidence for the TAMP™ Therapy Platform’s Novel, Localized Approach to Targeted Chemotherapeutic Delivery via Additional Pharmacokinetic and Pharmacodynamic DataMOUNTAIN VIEW, Calif., Dec. 11, 2025 (GLOBE N